Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Prostatic Angiogenic Responses in Late Life: Antiangiogenic Therapy Influences and Relation With the Glandular Microenvironment in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Model

Texto completo
Autor(es):
Montico, Fabio [1] ; Kido, Larissa Akemi [1] ; Hetzl, Amanda Cia [1] ; Alves Cagnon, Valeria Helena [1]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Univ Campinas Unicamp, Inst Biol, Dept Struct & Funct Biol, Sao Paulo - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo Científico
Fonte: PROSTATE; v. 75, n. 5, p. 484-499, APR 1 2015.
Citações Web of Science: 10
Resumo

BACKGROUNDAging is considered one of the main predisposing factors for the development of prostate malignancies. Angiogenesis is fundamental for tumor growth and its inhibition represents a promising therapeutic approach in cancer treatment. Thus, we sought to determine angiogenic responses and the effects of antiangiogenic therapy in the mouse prostate during late life, comparing these findings with the prostatic microenvironment in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model. METHODSMale mice (52 week-old FVB) were submitted to treatments with SU5416 (6mg/kg; i.p.) and/or TNP-470 (15mg/kg;s.c.). Finasteride was administered (20mg/kg;s.c.), alone or in association to both inhibitors. The dorsolateral prostate was collected for VEGF, HIF-1, FGF-2 and endostatin immunohistochemical and Western Blotting analyses and for microvessel density (MVD) count. RESULTSSenescence led to increased MVD and VEGF, HIF-1 and FGF-2 protein levels in the prostatic microenvironment, similarly to what was observed in TRAMP mice prostate. The angiogenic process was impaired in all the treated groups, demonstrating significantly decreased MVD. Antiangiogenic and/or finasteride treatments resulted in decreased VEGF and HIF-1 levels, especially following TNP-470 administration, either alone or associated to SU5416. The combination of these agents resulted in increased endostatin levels, regardless of the presence of finasteride. CONCLUSIONSProstatic angiogenesis stimulation during senescence favored the development of neoplastic lesions, considering the pro-angiogenic microenvironment as a common aspect also observed during cancer progression in TRAMP mice. The combined antiangiogenic therapy was more efficient, leading to enhanced imbalance towards angiogenic inhibition in the organ. Finally, finasteride administration might secondarily upregulate the expression of pro-angiogenic factors, pointing to the harmful effects of this therapy. Prostate 75: 484-499, 2015. (c) 2014 Wiley Periodicals, Inc. (AU)

Processo FAPESP: 10/51112-5 - Terapias antigênicas e caracterização das células-tronco prostáticas (CTP) normais e cancerosas no modelo de camundongo transgênico para adenocarcinoma de próstata (TRAMP)
Beneficiário:Valéria Helena Alves Cagnon Quitete
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 11/01968-3 - Estroma reativo e próstata: senescência e inibição da angiogênese x lesões glandulares no modelo TRAMP
Beneficiário:Fabio Montico
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 12/03010-4 - Caracaterização molecular da próstata frente às terapias hormonais e antiangiogênicas em camundongos senis (FVB) e no modelo transgênicos (Tramp) para adenocarcinoma de próstata
Beneficiário:Valéria Helena Alves Cagnon Quitete
Linha de fomento: Auxílio à Pesquisa - Regular